NCT00688116

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Synta Pharmaceuticals Corp. · Industry
• Sex: All
• Age: 25 Years
• Healthy volunteers: Not accepted

Summary

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

Detailed description

This is an open-label Phase 1 dose-escalation study in patients with solid tumors treated with STA-9090 (ganetespib) to evaluate for safety, tolerance and efficacy.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	STA 9090 (ganetespib)	This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., \[Monday, Thursday\] or \[Tuesday, Friday\]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.

Timeline

• Start date: 2007-10-01
• Primary completion: 2014-04-01
• Completion: 2014-11-01
• First posted: 2008-06-02
• Last updated: 2014-09-18

Locations

5 sites across 1 country: United States